BOSTON and SYDNEY – 28 March 2018 – GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announced that it will release its 2017 Annual Report on Form 10K on or before 31 March EDT | 1 April AEST 2018.

GI Dynamics will hold a shareholder call to provide a financial update at 6:00 PM EDT on 2 April 2018 | 8:00 AM AEST on 3 April 2018.

Shareholder Call:                                                                                                 

Please dial-in five minutes prior to the start of the call. Regional dial-in numbers are as follows:

United States (Toll-Free):                                        877 407 6184

Australia (Toll-Free):                                                1 800 687 004

United Kingdom (Toll-Free):                                    0 800 756 3429

Germany (Toll-Free):                                                0 800 182 0040

Switzerland (Toll Free):                                            800 835 525

For all other regions or if you are unable to access the call through any of the above numbers please dial the toll number as follows:

International (Toll; charges will apply):                 201 389 0877

The transcript and audio recording will be available on the company’s website shortly following the call.

 

About GI Dynamics

GI Dynamics®, Inc. (ASX:GID) is the developer of EndoBarrier, the first endoscopically-delivered device therapy for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale and is limited by federal law to investigational use only. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information please visit www.gidynamics.com.

Forward-Looking Statements

This announcement may contain forward-looking statements. These forward-looking statements are based on GI Dynamics management’s current estimates and expectations of future events as of the date of this announcement. Furthermore, the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with our ability to continue to operate as a going concern, our ability to maintain compliance with our obligations under the Convertible Loan Note executed with Crystal Amber Fund Limited, obtaining and maintaining regulatory approvals required to market and sell our products; obtaining funding from third parties; the consequences of stopping the ENDO trial and the possibility that future clinical trials will not be successful or confirm earlier results; the timing and costs of clinical trials; the timing of regulatory submissions; the timing, receipt and maintenance of regulatory approvals; the timing and amount of other expenses; the timing and extent of third-party reimbursement; intellectual-property risk; risks related to excess inventory; and risks related to assumptions regarding the size of the available market, the benefits of our products, product pricing, timing of product launches, future financial results and other factors, including those described in our filings with the U.S. Securities and Exchange Commission. Given these uncertainties, one should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless we are required to do so by law.

###